Key statistics dashboard for Kymera Therapeutics, Inc. (KYMR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Stock Data
| Price | $116.33 |
| Market Cap | $9.6B |
| Enterprise Value | $9.53B |
| Beta | 2.29 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -35.78 |
| Price / Book | 7.56 |
| P/S | 91.11 |
| EV/EBITDA | -32.54 |
| EV/Sales | 90.74 |
| EV/FCF | -40.04 |
| P/FCF | -40.20 |
| Earnings Yield | -2.62% |
| FCF Yield | -2.49% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 101.98% |
| EBIT Margin | -285.42% |
| EBITDA Margin | -278.85% |
| Operating Margin | -333.54% |
| Net Margin | -285.41% |
| Return on Equity | -21.50% |
| Return on Assets | -18.21% |
| Return on Invested Capital | -22.14% |
| Return on Capital Employed | -22.30% |
Financial Health
| Current Ratio | 9.83 |
| Quick Ratio | 9.91 |
| Cash Ratio | 1.66 |
| Debt / Equity | 0.05 |
| Debt / Assets | 5.00% |
| Net Debt / EBITDA | 0.14 |
| Interest Coverage | -1659.61 |
Per-Share Data
| Revenue per share | 1.07 |
| Book Value per share | 15.34 |
| Cash per share | 7.04 |
| FCF per share | -2.42 |
| Tangible Book Value per share | 15.34 |
| Dividend per share | 0.00 |
Related companies: AAPG · ACAD · ACLX · AKRO · CRNX · IMVT · NAMS
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks